Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse

J Neurol. 2020 Oct;267(10):2803-2805. doi: 10.1007/s00415-020-09921-1. Epub 2020 May 28.

Authors

Nora Möhn¹, Firas Saker¹, Viktoria Bonda¹, Gesine Respondek¹, Marcus Bachmann², Matthias Stoll², Mike P Wattjes³, Martin Stangel¹, Thomas Skripuletz⁴

Affiliations

¹ Department of Neurology, Hannover Medical School, Hannover, Germany.
² Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
³ Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany.
⁴ Department of Neurology, Hannover Medical School, Hannover, Germany. skripuletz.thomas@MH-Hannover.de.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use*
Betacoronavirus
COVID-19
Coronavirus Infections / complications*
Crotonates / therapeutic use
Humans
Hydroxybutyrates
Male
Methylprednisolone / therapeutic use*
Multiple Sclerosis, Relapsing-Remitting / complications*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Nitriles
Pandemics
Pneumonia, Viral / complications*
Recurrence
SARS-CoV-2
Toluidines / therapeutic use

Substances

Anti-Inflammatory Agents
Crotonates
Hydroxybutyrates
Nitriles
Toluidines
teriflunomide
Methylprednisolone